R 112

Drug Profile

R 112

Alternative Names: R 926112; R112

Latest Information Update: 11 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigel Pharmaceuticals
  • Class Antiallergics
  • Mechanism of Action Mast cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic rhinitis

Most Recent Events

  • 30 Dec 2005 Phase II trials have been completed in Allergic rhinitis in the US
  • 14 Jul 2005 A study has been added to the adverse events and Obstructive Airways Disease therapeutic trials sections
  • 18 Mar 2005 Data from a media release have been added to the Obstructive Airways Disease therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top